Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Renewable Partners

Innovative Industrial Properties

They're resilient and already offer attractive dividends.

3 Dividend Stocks to Buy If the Stock Market Crashes

Will Johnson & Johnson Win Authorization for Its COVID-19 Booster?

Duke Energy

Alphabet

This stock trio is perfectly positioned to help investors navigate a possible downturn.

The Safest Stocks to Buy if There's a Stock Market Crash

Intel

Netflix

Procter & Gamble

Snap

Tesla

The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporting docket.

Into the Heart of Q3 Earnings Season

Millions of Americans are likely to get Johnson & Johnson boosters now that the FDA's expert panel has unanimously recommended it.

J&J boosters are on the horizon for everyone who got that shot - regardless of age, job, or health

Members of the Food and Drug Administration's key advisory committee on vaccines criticized the speed with which the agency was reviewing Johnson & Johnson's Covid booster trials as well as the lack of verified data presented before the panel Friday.

Scientists question FDA on 'scant' J&J booster data and speedy review

NEW BRUNSWICK, N.J., Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

The advisers unanimously voted that those who got the one-dose vaccine should get a booster at least two months later.

FDA panel recommends Johnson & Johnson COVID booster for people 18 and up

The CDC has released data breaking down COVID-19 cases and deaths by vaccination status, as well as vaccine brand.

CDC data confirms J&J is the worst-performing COVID-19 vaccine in the US - but being unvaccinated is far more dangerous

The recommendation of the independent panel of experts is typically followed by the FDA.

FDA Advisory Committee Recommends Booster Shots Of J&J Vaccine For People 18 And Older

The Food and Drug Administration should authorize a second “booster” dose of Johnson & Johnson's JNJ, +0.89% COVID-19 vaccine for adults who were initially vaccinated with this vaccine, according to a group of scientists and clinicians that advises the regulator.

FDA committee says it's safe for all adults who got J&J's COVID-19 vaccine to get a booster

An FDA advisory committee said the agency should authorize boosters of J&J's single-shot vaccine to the more than 15 million Americans who received the initial dose.

FDA panel unanimously recommends J&J Covid booster shots to adults who already got the first dose

The FDA's advisors voted 19-0 in favor of offering J&J recipients a second dose as soon as two months after they got the first shot.

A Johnson & Johnson booster shot just got closer to reality, as the FDA's expert panel unanimously supports an extra dose

Halliburton

Philip Morris

Steel Dynamics

The first week of the September-quarter earnings season is now in the books. At a glance, of 24 companies we followed that reported quarterly results this week, only two missed profit estimates and only three missed revenue forecasts.

Earnings Previews: Halliburton, Johnson & Johnson, Philip Morris, Procter & Gamble, Steel Dynamics

Johnson & Johnson (NYSE: JNJ) put its obligations for tens of thousands of cases tying talc-based products to cancer into bankruptcy. The company hopes the action will help push a personal injury claims settlement.

Explained here why Johnson & Johnson is setting a $2 billion trust

Moderna

These are Insider's biggest healthcare stories for the week ending October 15.

What's in store for Moderna and J&J booster shots

Johnson & Johnson has filed for voluntary Chapter 11 bankruptcy protection for a subsidiary set up to handle legal claims over allegations that the drugmaker's Baby Powder and other cosmetic talc products contain asbestos and cause cancer. J&J is facing litigation from tens of thousands of people, including women suffering from ovarian cancer and mesothelioma.

J&J puts talc claims subsidiary into bankruptcy

Pfizer

The bar could be lower for the FDA to authorize booster shots for J&J's COVID-19 vaccine.

Could Johnson & Johnson's Booster Opportunity Be Better Than Pfizer's and Moderna's?

J&J says it will establish a $2 billion trust to pay amounts the bankruptcy court determines that its LTL Management subsidiary owes.

Johnson & Johnson Puts Unit Holding Talc Claims Into Bankruptcy

CHARLOTTE, N.C., Oct. 14, 2021 /PRNewswire/ -- Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use bankruptcy to avoid legal responsibility for the cancers tied to those products.

Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme

Johnson & Johnson placed into bankruptcy its liabilities for tens of thousands of claims linking talc-based products to cancer, hoping to drive a settlement of personal-injury claims that are expected to grow for decades to come.

The Wall Street Journal: Johnson & Johnson places its talc liabilities into bankruptcy

Johnson & Johnson said on Thursday its newly created unit that was established to hold and manage claims in the Baby Powder litigation, has filed for voluntary Chapter 11 bankruptcy protection.

J&J unit to manage talc claims files for bankruptcy protection

NEW BRUNSWICK, N.J., Oct. 14, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litigation, has filed for voluntary Chapter 11 bankruptcy protection.

Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims

J&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.

J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study Finds

AbbVie

Coca-Cola

With the market 22% historically overvalued, many of the world's best blue-chips are trading at unattractive levels. In fact, Bank of America thinks stocks will barely deliver positive returns over the next decade.

News for Johnson & Johnson Stock (JNJ)